INTRODUCTION
============

In 1972, Guillemin's group -- while searching for additional releasing factors in hypothalamic extracts after their identification of thyrotropin-releasing hormone (TRH) -- identified a novel negative regulator of pituitary somatotropic cells releasing growth hormone (GH; [@B8]). The cyclo peptide was named somatostatin (somatotropin release-inhibiting factor, SRIF), in keeping with its hypophysiotropic action ([@B56]). Somatostatin was found to be expressed in two biologically active isoforms: the tetradecapeptide somatostatin-14 ([@B8]) and the amino terminally extended octacosapeptide somatostatin-28 generated by differential post-translational processing from a common precursor molecule ([@B97]). Thereafter, a flow of articles in rodents and humans established the ubiquitous distribution of somatostatin in various brain areas ([@B44]; [@B63]; [@B155]) and peripheral organs including the gastrointestinal tract ([@B19]; [@B161]). This was followed by the identification and characterization of five distinct, high-affinity, specific somatostatin receptors (sst) encoded by five distinct genes ([@B47]). Structurally, these receptors belong to the so-called "superfamily" of membrane G protein-coupled (GPC) receptors. The sst~1-5~ have distinct as well as overlapping patterns of distribution in the brain ([@B41]; [@B124]) and gut ([@B111]; [@B77]; [@B18]) with a prominent expression of sst~2~ in the gastrointestinal tract ([@B136]). Studies using new pharmacological tools, namely selective sst subtype agonists and antagonists ([@B53]; [@B14]; [@B40], [@B39]; **Table [1](#T1){ref-type="table"}**) point toward the role of different sst~1-5~ in mediating the large spectrum of somatostatin biological actions, mostly inhibitory in nature. Multiple effects of somatostatin can also result from the ability of sst to form both homodimers or heterodimers (sst~5~ with sst~1~ or dopamine D~2~ receptor, sst~2a~ with sst~3~, D~2~ or μ opioid receptor subtype 1) resulting in the activation of different intracellular signaling cascades ([@B102]; [@B3]; [@B121]).

###### 

Structure and receptor binding affinity of somatostatin and somatostatin receptor agonists.

  Peptide                      Structure                                                                                                                 Receptor binding affinity (IC~50~, nM)^a^                                            
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ------------ -------------- ------------ -------------
  Somatostatin-14 ([@B158])    Ala-Gly-c\[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys\]-OH                                                           0.1--1.5                                    1.7          1.7            1.0--1.6     0.2--2.2
  Somatostatin-28 ([@B158])    Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-c\[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys\]-OH   0.1--4.7                                    0.4--5.2     0.2            0.3--1.1     0.05--0.19
  Octreotide ([@B54])          H-(D)-Phe^2^-c\[Cys^3^-Phe^7^-DTrp^8^-Lys^9^-Thr^10^-Cys^14^\]-Thr^15^(ol)                                                \>1K                                        1.9 ± 0.3    39 ± 14        \>1K         5.1 ± 1.1
  ODT8-SST ([@B40])            des-AA^1,2,4,5,12,13^-(DTrp^8^)-SST                                                                                       27.0 ± 3.4                                  41.0 ± 8.7   13.0 ± 3.2     1.8 ± 0.7    46.0 ± 27.0
  Cortistatin-17 ([@B46])      Asp-Arg-Met-Pro-cyclo-\[Cys-Arg-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys\]Lys                                              0.3--7.0                                    0.6--0.9     0.4--0.6       0.5--0.6     0.3--0.4
  sst~1~ agonist ([@B39])      des-AA^1,4-6,10,12,13^-\[DTyr^2^,D-Agl(NMe,2naphtoyl)^8^,IAmp^9^\]-SST-Thr-NH~2~                                          0.19 ± 0.04                                 \>1K         158.0 ± 14.0   27.0 ± 7.5   \>1K
  sst~2~ agonist ([@B53])      des-AA^1,4-6,11-13^-\[DPhe^2^,Aph^7^(Cbm),DTrp^8^\]-Cbm-SST-Thr-NH~2~                                                     \>1K                                        7.5--20      942--1094      872--957     109--260
  sst~2~ antagonist ([@B14])   des-AA^1,4-6,11-13^-\[pNO~2~-Phe^2^,DCys^3^,Tyr^7^,DAph(Cbm)^8^\]-SST-2Nal-NH~2~                                          \>1K                                        2.6 ± 0.7    384.0 ± 97.0   \>1K         \>1K

Receptor affinities were derived from competitive radioligand displacement assays in cells stably expressing the cloned human receptor using
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Of interest to neuroendocrinologists, somatostatin's inhibitory action on pituitary GH release was soon extended to a wide range of hypophyseal hormones including prolactin, thyrotropin (thyroid-stimulating hormone, TSH), and adrenocorticotropic hormone (ACTH; [@B13]; [@B6]; [@B118]) as well as a large number of hormones secreted from endocrine cells of the gastrointestinal tract including gastrin ([@B75]), cholecystokinin (CCK; [@B119]), secretin ([@B119]), gastric inhibitory peptide (GIP; [@B94]), and neurotensin ([@B104]), and from the pancreas glucagon ([@B81]; [@B138]), insulin ([@B94]; [@B81]; [@B138]), and pancreatic polypeptide (PP; [@B81]). Studies to characterize the somatostatin receptor subtypes established that sst~2~ is primarily involved and, to a smaller extent, sst~5~ in the broad inhibitory effects of somatostatin on endocrine secretion ([@B75]; [@B138]; [@B31]). Of clinical relevance was also the compelling evidence that the majority of neuroendocrine tumors (NETs) expressed increased levels of sst~2~ leading to the development of radiolabeled peptides and peptide receptor radionuclides as diagnostic and therapeutic tools respectively for NETs ([@B156]; [@B20]; [@B50]; [@B62]).

In the past decade, a significant breakthrough came from the identification of a 28-amino-acid octanoylated peptide, ghrelin in the endocrine cells of the gastric mucosa as the cognate ligand for the GH-secretagogue receptor 1a (GHS-R~1a~, later renamed ghrelin receptor, GRLN-R; [@B68]; [@B26]). Ghrelin's interaction with the GRLN-R represents a third independent regulatory pathway controlling the pulsatile release of pituitary GH besides the GH-releasing hormone (GHRH) and somatostatin ([@B68]; [@B80]; [@B66]).

Consistent with ghrelin, being predominantly produced by the endocrine cells of the stomach ([@B1]), recent studies also documented that gastrointestinal NETs released ghrelin ([@B15]; [@B154]). Therefore the regulation of ghrelin release by somatostatin will be of clinical relevance. The present review focuses on recent evidence that somatostatin signaling in the brain and the periphery exerts opposite influence on circulating ghrelin levels. The sst receptor subtype(s) involved and functional relevance of somatostatin-induced altered ghrelin plasma levels in the context of orexigenic and gastric prokinetic actions of the peptide ([@B69]) will also be addressed.

SOMATOSTATIN AND ITS RECEPTORS: EXPRESSION AND MODULATION OF FEEDING BEHAVIOR AND GASTROINTESTINAL MOTILITY
===========================================================================================================

EXPRESSION OF SOMATOSTATIN AND sst
----------------------------------

Somatostatin is expressed throughout the brain except in the cerebellum ([@B44]; [@B63]). Peptide distribution has been investigated by immunohistochemistry indicating the expression in the cortex, limbic system, central nucleus of the amygdala, sensory structures, hypothalamus (including the arcuate, ventromedial, and paraventricular nucleus), and the periaqueductal central gray ([@B44]; [@B63]; [@B83]). Similarly, sst receptor mRNA expression is widely detected in the rat brain including the deep layers of the cerebral cortex, bed nucleus of the stria terminalis, basolateral amygdaloid nucleus, medial amygdaloid nucleus, paraventricular thalamic nucleus, medial preoptic nucleus, dorsomedial and ventromedial hypothalamic nucleus, arcuate and paraventricular nucleus of the hypothalamus, substantia nigra, dorsal raphe nucleus, granular layer of the cerebellum, locus coeruleus, nucleus of the solitary tract, and the dorsal motor nucleus of the vagus nerve ([@B41]; [@B124]). The wide distribution of the ligand along with the receptors is consistent with the pleiotropic action of the sst signaling systems.

Somatostatin is widely expressed in the gastrointestinal tract and the pancreas, namely in endocrine mucosal D cells scattered within the stomach, small and large intestine, and in δ-cells of the pancreatic islets of Langerhans ([@B161]). In addition, somatostatin is also detected in neurons of the gut enteric nervous system within both the submucosal and myenteric plexus ([@B19]). Similar to the ligand, sst receptor subtypes are widely expressed in the gastrointestinal tract. In rats, mRNA expression of sst~1~, sst~2~, sst~3~, and sst~4~ is detected in the small and large intestine without any clear predominance to one segment ([@B111]). The sst~1~ is the predominant form in gastrointestinal tract of mice, whereas the sst~5~ was almost undetectable ([@B111]). In human colon, a differential expression has been reported with sst~2~ mRNA expression on circular smooth muscle cells and sst~1-3~ mRNA on longitudinal muscle layer cells ([@B18]). Interestingly, in the pancreas protein expression of all sst~1-5~ receptor subtypes has been identified on every major endocrine cell type, namely α, β, δ, and PP cells with a differential expression pattern between species ([@B77]).

BRAIN ACTIONS OF SOMATOSTATIN
-----------------------------

The first function assigned to somatostatin was the inhibition of GH release ([@B8]). Now somatostatin is recognized to exert several central extrapituitary actions such as the regulation of other pituitary endocrine hormones especially those responsive to stress, parasympathetic and sympathetic outflow, thermogenesis, visceral functions, and behaviors. Namely, intracerebroventricular (icv) injection of somatostatin-28 inhibited the tail suspension stress-induced rise of circulating ACTH ([@B13]). This effect was mimicked by the stable pan-somatostatin agonist, ODT8-SST but not by somatostatin-14 ([@B13]). The sst~2~ seems to play a pivotal role in these regulatory processes as sst~2~ receptor knockout mice display an increased ACTH release compared to their wild type littermates ([@B159]).

With regard to the central actions of somatostatin to affect visceral functions, recent studies have focused on the gastrointestinal tract. ODT8-SST injected intracisternally (ic) in rats accelerated gastric emptying of a liquid non-nutrient solution. This effect is mimicked by somatostatin-28 and the sst~5~ preferring agonist, BIM-23052 but not somatostatin-14 or the agonists preferring sst~1~, CH-275, sst~2~, DC-32-87, sst~3~, BIM-23056, and sst~4~, L-803,087 ([@B82]) indicating a prominent role of brain sst~5~ activation to induce a gastroprokinetic effect. This contention is further corroborated by the prominent mRNA expression of sst~5~ in the dorsal motor nucleus of the vagus nerve ([@B147]). Since sst receptors are also expressed in hypothalamic brain nuclei regulating colonic functions ([@B84]; [@B85]; [@B146]) including the arcuate (sst~1-5~; [@B41]; [@B112]) and paraventricular nucleus of the hypothalamus (sst~2-4~; [@B41]; [@B112]) and the locus coeruleus (sst~2-4~; [@B41]; [@B112]), several studies investigated whether activation of central somatostatin signaling influences colonic motor functions. Stressing mice by short exposure to anesthesia vapor and icv injection of vehicle robustly stimulated propulsive colonic motor function shown by a 99% increase in fecal pellet output ([@B132]). This effect was completely abolished by icv pretreatment with ODT8-SST, somatostatin-28 and the selective sst~1~ agonist, whereas sst~2~ or sst~4~ agonists or octreotide (**Table [1](#T1){ref-type="table"}**) had no effect. These data suggest that activation of brain sst~1~ can prevent the stress-related stimulation of colonic propulsive motor function in mice ([@B132]).

Central somatostatin alters food intake with a divergent action depending on the doses used: an increase is induced by icv injection of lower (picomolar) doses and a decrease following high (nanomolar) in rats ([@B42]). The stable pan-somatostatin agonist, ODT8-SST ([@B40]) icv stimulated food intake in rats under basal as well as already stimulated conditions during the dark phase with a rapid onset (during the first hour) and a long duration of action (lasting for 4 h; [@B126]). ODT8-SST's orexigenic action is sst~2~ mediated as it is reproduced by icv injection of the selective peptide sst~2~ agonist ([@B129]) and blocked by the selective peptide sst~2~ antagonist ([@B126]). This represents a central action since injected intraperitoneally at a 30-fold higher dose, the peptide did not influence food intake ([@B129]). The orexigenic effect of central sst~2~ stimulation observed in rats has been recently expanded to mice ([@B128]). A detailed analysis of the food intake microstructure using an automated food intake monitoring device showed that icv injection of the sst~2~ agonist increased the number of meals, shortened inter-meal intervals, and induced a higher rate of ingestion, whereas meal sizes were not altered ([@B128]). Collectively, these data indicate that brain activation of sst~2~ signaling pathways in rodents induces a rapid orexigenic response by decreasing satiety (number of meals), without influencing satiation indicated by normal meal sizes ([@B128]). The physiological role of brain sst~2~ signaling in modulating food intake is also supported by the decrease of nocturnal food intake induced by the peptide sst~2~ antagonist injected icv at the beginning of the dark phase ([@B129]). In addition, hypothalamic somatostatin shows a circadian rhythm with a peak in the early dark phase and a nadir in the early light phase ([@B49]). Moreover, food restriction increases pituitary somatostatin release ([@B59]) which could increase the drive to eat under these conditions.

PERIPHERAL ACTIONS OF SOMATOSTATIN
----------------------------------

Contrasting to the central effects, somatostatin's actions in the periphery are largely inhibitory. In the stomach, somatostatin delays emptying of the food ([@B123]) and inhibits gastric acid secretion which is mediated directly by an interaction with acid producing parietal cells but also via the reduced release of histamine from ECL cells and gastrin from G cells ([@B161]). The acid-antisecretory action of somatostatin is no longer observed in sst~2~ knockout mice, indicative of a primary role of the sst~2~ ([@B96]). Similarly, in the small intestine somatostatin reduces intestinal peristalsis in cats, rabbits and rats, while stimulating the duodenal, jejunal, and ileal contractile response in dogs ([@B145]). In line with the findings in rodents, somatostatin increases gastrointestinal transit time in humans ([@B55]). The effects on colonic motility are likely mediated by the sst~1~ and sst~2~ based on *in vitro* studies using circular and longitudinal human colonic smooth muscle cells ([@B18]). In addition, somatostatin reduces visceral sensitivity with the sst~2~ playing a key role as indicated by visceral hypersensitivity to both mechanical and chemical stimulation in the jejunum of sst~2~ knockout mice ([@B105]). This finding is likely to be relevant in humans as well. Patients with irritable bowel syndrome injected subcutaneously with octreotide display an anti-hyperalgesic response as shown by the increased threshold of discomfort and pain using rectal barostat manometry compared to injection of placebo ([@B7]; [@B113]).

GHRELIN AND ITS RECEPTOR: EXPRESSION AND PHYSIOLOGICAL OREXIGENIC AND PROKINETIC ACTIONS
========================================================================================

EXPRESSION AND REGULATION OF GHRELIN AND GHRELIN RECEPTOR
---------------------------------------------------------

Ghrelin bears a unique fatty acid (*n*-octanoyl) residue on the third amino acid which is essential for affinity and binding to the GRLN-R ([@B67]; [@B69]). Other dietary fatty acids of medium length can also serve as a direct source for the acylation of ghrelin ([@B88]). The enzyme catalyzing the acylation of ghrelin was unknown for several years and just recently identified in mouse and human as a member of the membrane-bound *O*-acyltransferases (MBOATs), namely MBOAT4 which was subsequently renamed ghrelin-*O*-acyltransferase (GOAT; [@B57]; [@B169]). GOAT mRNA and protein are prominently expressed in rodent and human gastric mucosa in ghrelin expressing cells ([@B108]; [@B131]). In addition, GOAT protein has been detected in rodent and human intestine, pancreatic duct, gallbladder, hypothalamus and pituitary gland ([@B48]; [@B73]; [@B64]), rodent plasma ([@B131]) and human visceral and subcutaneous adipocytes ([@B103]) leading to the speculation of additional acylation sites of ghrelin.

Unlike ghrelin, desacyl ghrelin, which does not bear the hydrophobic residue on the third amino acid, is the main circulating form. The acyl:desacyl ghrelin ratio is 1:3 as recently reported using an optimized blood processing protocol to improve the yield of acylated ghrelin in rats ([@B135]). Although desacyl ghrelin does not bind to and activate the GRLN-R ([@B67]), recent studies indicate that the peptide exerts several biological actions to influence food intake ([@B130]), reduce inflammatory somatic pain ([@B120]), muscle cachexia produced by injury in rats ([@B116]) and basal autophagy in human visceral adipocytes ([@B103]). However, the understanding of the physiological function of this peptide is hampered by the fact that the desacyl ghrelin receptor mediating its effects is still to be identified.

Blood levels of ghrelin vary in relation with the meal pattern with an increase before meals and a decrease thereafter ([@B21]; [@B152]). In addition, fasting also increases ghrelin mRNA expression ([@B149]; [@B65]; [@B165]) and reduces ghrelin peptide content in the stomach ([@B149]; [@B65]) indicative of a stimulated production and release under conditions of food deprivation. Ghrelin levels are not only regulated by short-term variations in energy status associated with meal patterns but also by long-term changes in body weight. Ghrelin plasma levels are elevated under conditions of reduced body weight such as anorexia nervosa or tumor cachexia and reduced in obesity ([@B151], [@B153]; [@B22]). Similar to the ligand, the ghrelin acylating enzyme, GOAT is regulated by the metabolic status with an increased GOAT mRNA and protein expression in rodent gastric mucosa, hypothalamus, and pituitary following a 12- or 24-h fast ([@B51]; [@B48]; [@B131]). Under conditions of obesity induced by high fat diet or leptin deficiency in *ob/ob* mice, a down-regulation of GOAT mRNA occurred in the mouse pituitary, unlike the stomach or hypothalamus ([@B48]), while patients with obesity-associated type 2 diabetes showed higher levels of GOAT in visceral adipose tissue ([@B103]). This indicates a tissue specific regulation of GOAT under conditions of obesity.

OREXIGENIC AND PROKINETIC EFFECTS OF GHRELIN
--------------------------------------------

Ghrelin is well established to stimulate food intake in line with its regulation by changes in energy status in many species including humans ([@B163]; [@B144]; [@B37]). It is so far the only known peripherally produced and centrally acting orexigenic peptide, contrasting with the numerous anorexigenic peptides in the gut ([@B141]). Ghrelin's action is blocked by pharmacological or genetic approaches using GRLN-R antagonists ([@B109]) and GRLN-R knockout mice ([@B140]; [@B170]) indicating a key role of ghrelin-GRLN-R interaction in mediating the orexigenic response. The food intake stimulatory action can result from ghrelin crossing the blood--brain barrier and binding to GRLN-R expressed on food intake regulatory brain nuclei ([@B2]; [@B90]) or acting directly on vagal afferents which also bear the ghrelin receptor ([@B25]; [@B107]). The respective role of these pathways under nutritional changes is still to be delineated. In addition to the stimulation of food intake, ghrelin is also involved in the regulation of body weight inducing an increase of body weight following chronic infusion of the peptide. This occurs through combined actions of stimulating appetite along with increasing fat storage and reducing lipid mobilization ([@B151]; [@B137]; [@B27]). Further corroborating these findings, ghrelin and GRLN-R double knockout mice display an increased energy expenditure leading to a reduction of body weight ([@B95]) which, however, could not be reproduced with a single genetic deletion of either ghrelin ([@B139]; [@B95]) or the GRLN-R ([@B95]). These differential phenotypes may reflect the functional relevance of the high constitutive activity of the GRLN-R ([@B24]) and also give rise to the speculation that additional ligands for the receptor may exist ([@B28]).

DIFFERENTIAL MODULATION OF GH RELEASE BY GHRELIN AND SOMATOSTATIN
=================================================================

Ghrelin exerts endocrine actions opposite to somatostatin by stimulating anterior pituitary release of GH ([@B67]; [@B167]; [@B70]), prolactin, and ACTH ([@B72]). Somatostatin's GH inhibitory effect is mediated by the sst~2~ ([@B9]), sst~5~ ([@B110]) and also sst~1~ ([@B71]). The GH releasing effect of ghrelin is blunted by intravenous (iv) infusion of somatostatin in healthy volunteers ([@B36]) and was completely blocked in pig pituitary cells *in vitro* ([@B80]). The GH releasing action of ghrelin is likely to not only result from inhibiting somatostatin release ([@B43]) but also from direct activation of GH release ([@B157]). In addition, ghrelin and somatostatin antagonistically interact on hypothalamic arcuate cells to regulate the release of GHRH with an activation of these neurons following ghrelin and a reduction after application of somatostatin *in vitro* ([@B86]).

ACTIVATION OF BRAIN sst~2~ SIGNALING INCREASES BASAL AND PREVENTS VISCERAL STRESS-INDUCED SUPPRESSION OF CIRCULATING GHRELIN
============================================================================================================================

Based on the established centrally sst~2~-mediated orexigenic action of somatostatin ([@B126],[@B129]), we further investigated whether changes in circulating ghrelin may play a role. We found that the pan-somatostatin peptide, ODT8-SST (**Table [1](#T1){ref-type="table"}**) injected icv increased basal plasma acyl ghrelin levels in *ad libitum* fed rats ([@B126]). However, the rise was observed at 3 h postinjection and therefore unlikely to underlie the initial increase in food intake response to central ODT8-SST which occurred within the first hour. However, it may contribute to the sustained significant increase in cumulative food intake still maintained at 4 h after icv injection of ODT8-SST ([@B126]). Other studies showed that activation of brain sst~2~ receptor prevents the decline in circulating ghrelin induced by visceral stress. Abdominal surgery reproducibly decreased the fasting plasma levels of acyl and desacyl ghrelin with a rapid onset and long lasting effect in rats ([@B127], [@B133],[@B134]). Such a response was completely prevented by the ic injection of ODT8-SST as monitored 50 min postsurgery at a time where the peptide induces a 31 and 46% rise in fasting circulating acyl and desacyl ghrelin, respectively in sham animals ([@B133]). In addition, the sst~2~ selective peptide agonist injected ic also prevented the postoperative decline in plasma levels of acyl ghrelin, whereas sst~1~ and sst~4~ agonists (**Table [1](#T1){ref-type="table"}**) did not when tested under the same conditions ([@B133]).

Of interest was the demonstration that ic ODT8-SST or sst~2~ agonist in addition to preventing the decline in acyl ghrelin induced by abdominal surgery also blunted the postoperative suppression of food intake ([@B133]). However, the observed prevention of declining circulating ghrelin levels is not the main factor for the restoration of the orexigenic response postsurgically. The peripheral blockade of the GRLN-R using the GRLN-R antagonist (\[D-Lys^3^\]-GHRP-6) injected intraperitoneally did not modify the food intake stimulating effect of ic ODT8-SST ([@B133]). ODT8-SST injected icv also restored gastric emptying inhibited by abdominal surgery to levels observed under basal conditions, an effect mimicked by the sst~5~ but not the sst~1~, sst~2~, and sst~4~ agonists in rats ([@B133]). Similar to the effect on food intake, this action was not mediated by acyl ghrelin as the intraperitoneal injection of the GRLN-R antagonist did not influence the gastroprokinetic action of ODT8-SST postsurgery ([@B133]).

Taken together, these data indicate that the central activation of sst~2~ increases basal or prevents the surgical inhibition of circulating levels of ghrelin and food intake while activation of sst~5~ restores postoperative gastric ileus in rats. It also points to a differential role of brain sst subtypes 2 and 5 in preventing the stress-related suppression of ghrelin release/food intake and gastric emptying, respectively. In addition, the restoration of suppressed circulating acyl ghrelin levels after surgery does not play a major role as underlying mechanisms through which ODT8-SST injected into the brain exerts its prokinetic and orexigenic effects. Other studies showed that activation of sst~2~ and sst~5~ receptors in the brain inhibits stimulated CRF release in the hypothalamus and acute stress-related CRF mediated ACTH release ([@B13]; [@B148]; [@B106]; [@B150]). Brain CRF acting on CRF receptors is involved in the stress-related decrease in feeding behavior, ghrelin secretion, and gastric emptying ([@B58]; [@B114]; [@B143]; [@B166]). Therefore, it may be speculated that central activation of sst~2~ and/or sst~5~ dampens hypothalamic CRF activated by abdominal surgery ([@B162]) which may have a bearing with preventing the reduction in feeding, gastric emptying, and circulating ghrelin induced by abdominal surgery ([@B133]).

ACTIVATION OF PERIPHERAL sst~2~ SIGNALING INHIBITS CIRCULATING GHRELIN
======================================================================

In contrast to the rise in circulating ghrelin induced by central administration of somatostatin agonists, convergent *in vivo* and *in vitro* rodent studies established that somatostatin or the stable agonists octreotide and SOM230 act peripherally through the sst~2~ to reduce ghrelin release ([@B115]; [@B61]; [@B76]) resulting in lower circulating levels ([@B117]; [@B122]; [@B32]). Such a response is in line with the inhibitory effects of somatostatin-sst~2~ on the endocrine secretion of other intestinal hormones ([@B94]; [@B81]; [@B104]; [@B119]; [@B138]). Likewise, in humans, peripherally injected somatostatin ([@B12]; [@B89]) and somatostatin agonists such as octreotide ([@B4]) reduce circulating ghrelin in healthy subjects. Of relevance, chronic subcutaneous infusion of the sst~2~/sst~3~/sst~5~ agonist octreotide-induced suppression of ghrelin plasma levels is not subject to rapid desensitization in rats and is likely to be sst~2~ mediated based on the prominent sst~2~ mRNA expression in the rat stomach ([@B122]). Further support for a role of sst~2~ came from immunofluorescent double labeling studies detecting the protein expression of sst~2~ on ghrelin-producing X/A-like cells of the rat stomach ([@B134]) and similarly on human ghrelin-producing gastric mucosal P/D~1~ cells ([@B45]). Moreover, the selective peptide sst~2~ agonist (**Table [1](#T1){ref-type="table"}**) injected intravenously decreased circulating levels of acyl and desacyl ghrelin with a rapid onset (0.5 h) and a long duration of action (still visible at 2 h; [@B134]). Lastly, the selective peptide sst~2~ antagonist (**Table [1](#T1){ref-type="table"}**) injected intravenously prevents the decline in circulating ghrelin induced by the stimulation of endogenous peripheral somatostatin in rats ([@B134]).

The physiological role of peripheral somatostatin-sst~2~ signaling in the regulation of ghrelin was investigated under conditions of stimulation of endogenous gastric somatostatin. Urethane is well established to stimulate gastric somatostatin mRNA expression and peptide release in rats ([@B168]). Under these conditions, plasma ghrelin levels are decreased and the selective peptide sst~2~ antagonist (**Table [1](#T1){ref-type="table"}**) injected intravenously prevents the decline in circulating ghrelin induced by urethane ([@B134]). Convergent reports showed that abdominal surgery induces a rapid and sustained inhibition of circulating levels of ghrelin in rats ([@B127], [@B133],[@B134]). Likewise, iv injection of the selective peptide sst~2~ antagonist (**Table [1](#T1){ref-type="table"}**) blocked the abdominal surgery-induced decrease of plasma ghrelin at 0.5 h postsurgery ([@B134]). The peptide is likely to act through paracrine transmission since somatostatin positive D cells directly contact ghrelin immunoreactive X/A-like cells in the rat stomach ([@B117]). Interestingly, following abdominal surgery, acyl ghrelin was reduced more rapidly compared to desacyl ghrelin which was associated with a reduction of gastric as well as plasma concentrations of GOAT ([@B134]). Since blockade of peripheral sst~2~ signaling restores circulating levels of ghrelin ([@B134]), these data collectively suggest that peripheral somatostatin may blunt gastric GOAT mRNA expression and thereby negatively affect the acylation of ghrelin. In primary pituitary cell cultures somatostatin was reported to reduce GOAT mRNA expression and somatostatin knockout mice showed higher GOAT mRNA expression in the pituitary gland than the wild type ([@B48]). Based on these findings, somatostatin may influence ghrelin signaling not only *via* a direct inhibition of secretion but also by modulating the ghrelin activating enzyme GOAT. Further support for a physiological inhibitory action of peripheral somatostatin on ghrelin signaling came from somatostatin knockout mice that displayed an increased gastric ghrelin expression and higher circulating ghrelin levels compared to their wild type littermates ([@B78]). These data indicate that endogenous somatostatin exerts a physiological inhibitory tone on gastric ghrelin synthesis and release.

During the past years, several clinical studies described ghrelin-producing NETs ([@B91]; [@B160]; [@B142]) including six insulinomas, gastrinomas, vasoactive intestinal polypeptide (VIP)omas, non-functioning tumors ([@B160]) and as part of the multiple endocrine neoplasia type 1 (MEN-1; [@B60]; [@B99]; [@B38]). Moreover, ghrelinomas have been identified to originate from the stomach or pancreas and were associated with very high ghrelin levels ([@B15]; [@B154]). Growing evidence from clinical reports indicates that in addition to the surgical, chemotherapeutic, alpha-interferon, and local radiation treatments, the use of somatostatin or somatostatin analog is an established treatment option for gastroenteropancreatic NETs ([@B93]). Based on the evidence described above, the determination of the sst subtype expressed on those ghrelinoma tumor cells followed by the use of peripherally acting selective sst compounds may result in an even more targeted approach.

INTERACTION OF CORTISTATIN WITH GHRELIN SIGNALING
=================================================

In 1996, the discovery of a new peptide sharing 11 of its 14 amino acids with somatostatin-14 was named cortistatin based on its predominant cortical expression and ability to depress cortical activity ([@B33]). Despite the chemical structure homology with somatostatin, both peptides are derived from distinct genes ([@B35]). Similar to pro-somatostatin, processing of cortistatin precursor generated two mature products, cortistatin-14 and -29 in rodents and cortistatin-17 and -29 in humans ([@B46]; [@B125]). Cortistatin is widely expressed in the brain, namely in the cortex and hippocampus, and although regional overlap exists, the distribution pattern differs from that of somatostatin ([@B34]). Likewise, the peripheral expression pattern of cortistatin (e.g., in adrenal, thyroid, and parathyroid gland, testis, pancreas, kidney, lung, liver, stomach, ileum, jejunum, colon, endothelial, and immune cells) does not fully match that of somatostatin ([@B92]; [@B23]; [@B164]). Consistent with being a close somatostatin endogenous analog, cortistatin contains the FWKT tetramer crucial for sst binding, and therefore displays high-affinity (1--2 nM) to all five sst subtypes where the peptide acts as an agonist ([@B46]; [@B121]). However, emerging evidence indicates that cortistatin induces distinct central and peripheral effects that differ from those exerted by the somatostatin-sst interaction such as central acetylcholine release, reduction of locomotor activity, depression of cortical activity, induction of slow wave sleep, anti-inflammatory and immunomodulatory effects, and reduction of vascular calcium deposition (for review, see [@B125]; [@B11]; [@B52]).

The existence of a specific cortistatin receptor has not been identified yet but differential actions between somatostatin and cortistatin may possibly reside in the ability of cortistatin to bind and to activate the GRLN-R, whereas somatostatin does not ([@B29]; [@B87]). Divergent from native somatostatin, however, synthetic somatostatin agonists, lanreotide, octreotide, and vapreotide bind to the GRLN-R in human pituitary tissue ([@B30]) in addition to their selective affinity for sst~2~ \> sst~5~ \> sst~3~ ([@B5]; [@B101]; [@B100]). In addition to binding studies, few functional findings also support the possibility that cortistatin may be another endogenous high-affinity ligand of the GRLN-R. Cortistatin has been reported to inhibit vascular calcification induced experimentally in rats through activation of the GRLN-R receptor rather than sst or Mrg X2 ([@B74]). Of interest was the demonstration that cortistatin selectively upregulates the GRLN-R mRNA expression in cultured rat vascular smooth muscle cells, further indicative of an interaction between cortistatin and ghrelin signaling ([@B74]). Other studies in primates and mice demonstrated that endogenous cortistatin, unlike somatostatin, is involved in the stimulation of pituitary prolactin release, an effect that is blocked *in vitro* by the GRLN-R antagonist ([@B17]). However, most of the endocrine studies performed *in vivo* or *in vitro* showed parallel inhibitory responses between cortistatin and somatostatin consistent with the activation of classical sst subtypes ([@B10]) with some exceptions ([@B98]). This is further corroborated by the finding that cortistatin knockout mice display elevated circulating acyl ghrelin levels associated with an upregulated gastric ghrelin and GOAT expression ([@B17]) indicating an inhibitory tone of endogenous cortistatin on ghrelin signaling.

To further delineate the actions of cortistatin mediated *via* the GRLN-R another peptide, cortistatin-8, has been shown to bind to the GRLN-R while being devoid of affinity to the sst subtypes ([@B79]). However, in one clinical study cortistatin-8 did not influence spontaneous pituitary hormone secretion (GH, prolactin, and ACTH) and did not interfere with ghrelin's endocrine responses when given in equimolar dose ratios in healthy human subjects ([@B98]). Therefore, additional specific tools may be needed to characterize a possible direct link between the ghrelin and somatostatin signaling system *via* interaction on the GRLN-R.

SUMMARY
=======

In summary, somatostatin robustly affects circulating levels of ghrelin through interaction with the sst~2~. However, alterations vary with the site of action. Central somatostatin elevates plasma levels of acyl and desacyl ghrelin *via* interaction with brain sst~2~ and counteracts the visceral stress-related decrease in circulating ghrelin through pathways still to be elucidated in rodents. By contrast, the activation of peripheral somatostatin-sst~2~ inhibits circulating ghrelin levels in experimental and clinical studies and mediates the decline in circulating ghrelin induced by abdominal surgery in rodents likely *via* a paracrine action of somatostatin on sst~2~-bearing ghrelin cells in the stomach. Of interest, cortistatin, the other member of the somatostatin family, in addition to binding to sst~1-5~, also binds to and activates the GRLN-R. There is evidence that the peptide can exert a dual influence on ghrelin, by inhibiting its release through interaction with sst~2~ located on gastric ghrelin cells while activating GRLN-R at ghrelin's tissue targets.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by NIH R01 DK-33061, NIH Center Grant DK-41301 (Animal Core), VA Research Career Scientist and VA Merit grant (to Yvette Taché), German Research Foundation STE 1765/3-1 (to Andreas Stengel), and Charité University Funding UFF 89-441-176 (to Andreas Stengel).

[^1]: Edited by: *Hubert Vaudry, University of Rouen, France*

[^2]: Reviewed by: *Rafael Vazquez-Martinez, University of Cordoba, Spain; Francisco Gracia-Navarro, University of Cordoba, Spain*

[^3]: This article was submitted to Frontiers in Neuroendocrine Science, a specialty of Frontiers in Endocrinology.
